ArticleCureus2025
Standardization of a Molecular Technique for Human Papillomavirus Genotyping in a Public-Health Service.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo standardize a molecular technique for genotyping human papillomavirus (HPV) and to evaluate its distribution and relationship with vaginal cytology.
methodWomen aged 25 years or older with altered cytology were selected from three public-health hospitals and underwent HPV genotyping by molecular biology. Samples were processed, stored, and subjected to extraction and amplification. Amplification was performed for 28 HPV types (19 of high-risk and 9 types of low-risk). The frequencies of the most prevalent HPV types and those with multiple genotypes, were calculated. The association between categorical variables was analyzed using the chi-square (χ
resultsThe samples were divided into two groups: 1) without previous cervical treatment (177, 55%); and 2) with previous cervical treatment (142, 45%). The frequency of positive HPV was 126 (71%) and 67 (47%), respectively. The predominant high-risk HPVs were: 16, 58, 52 and 53; HPV53, HPV68 and HPV35 were associated with multiple infection in both groups. HPV16 and multiple infections were more prevalent between group age 25-35 years (
conclusionThe two groups differed in the frequency of HPV types and the chance of single and multiple infections. High-grade intraepithelial lesions were associated with HPV16 in both groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.